Included in the formulation
АТХ:B.01.A.D.11 Tenecteplase
Pharmacodynamics:The modified activator of natural plasminogen converts plasminogen into plasmin inside the thrombus. Plasmin leads to degradation of fibrinogen and dissolves clots of fibrin. Dose-dependent absorption of α2-antiplasmin, thereby increasing the systemic plasmin, which is an additional factor in the activation of plasminogen. With a single administration, the effect of recanalization of the coronary artery due to complete dissolution of the fibrin clot is noted.
Not has antigenic properties.
Pharmacokinetics:After intravenous administration, the therapeutic effect develops within 5 minutes. Metabolism in the liver.
The primary half-life is 20-30 minutes, the terminal half-life is 42-216 minutes. Elimination by the kidneys.
Indications:It is used to treat acute myocardial infarction.
IX.I20-I25.I21 Acute myocardial infarction
Contraindications:Bleeding, hemorrhagic vasculitis, arterial hypertension (with systolic pressure over 200 mmHg), a period of 3 months after the hemorrhagic stroke, acute pancreatitis, active form of tuberculosis, sepsis, individual intolerance, children under 18 years of age.
Carefully:Renal and hepatic insufficiency, the elderly age is over 75 years.
Pregnancy and lactation:Recommendations for FDA - Category C. It is used with caution during pregnancy and lactation in cases where the intended benefit exceeds the risk to the fetus and newborn.
Dosing and Administration:Intravenously, once, bolus, for 5-10 seconds, at a dose that depends on the patient's body weight.
The highest daily dose: 10 thousand units (50 mg).
The highest single dose: 10 thousand units (50 mg).
Side effects:Central and peripheral nervous system: rarely - intracranial hemorrhage.
Blood coagulation system: hemorrhages in the peri-and myocardium, hematoma, bleeding at the injection site, internal bleeding.
The cardiovascular system: reperfusion arrhythmia, bleeding from the puncture site, thromboembolism due to fragmentation of the thrombus.
Reproductive system: violation of the menstrual cycle.
Allergic reactions.
Overdose:Massive hemorrhage.
Treatment is symptomatic, blood transfusion.
Interaction:Pharmacologically incompatible with solutions of dextrose.
Simultaneous use with drugs that affect the blood coagulation system (anticoagulants, heparin, antiaggregants) increases the risk of bleeding.
Special instructions:The use of heparin after the administration of tenecteplase is possible no earlier than 4 hours later.